BACKGROUND AND OBJECTIVES: We examined retrospectively whether the combination of standard dacarbazine (DTIC) and/or fotemustine chemotherapy and autologous peptide-loaded dendritic cell (DC) vaccination may improve survival of stage IV melanoma patients. Furthermore, a small cohort of long-term survivors was studied in more detail. PATIENTS AND METHODS: Between 1998 and 2008, 41 patients were vaccinated at least three times with DCs while receiving chemotherapy and compared to all other 168 patients in our database who only received chemotherapy (1993-2008). RESULTS: Median life expectancy of patients receiving additional DC-vaccination was 18 months, compared to eleven months for patients under standard chemotherapy alone. In contrast to patients with other haplotypes, the HLA-A1/A1 subset of DC-treated patients showed significantly lower median survival (12 vs. 25 months). Autoantibodies were frequently detected in serum of both vaccinated and non-vaccinated patients, and there was no correlation between titers, loss or appearance of autoantibodies and survival. Additionally, phenotyping of DCs and PBMCs also did not reveal any conspicuous correlation with survival. CONCLUSIONS: Combining standard chemotherapy and DC vaccination appears superior to chemotherapy alone. The impact of HLA haplotypes on survival emphasizes the importance of a careful selection of patients with specific, well-defined HLA haplotypes for future vaccination trials using peptide-pulsed DCs, possibly combined with checkpoint inhibitors.
BACKGROUND AND OBJECTIVES: We examined retrospectively whether the combination of standard dacarbazine (DTIC) and/or fotemustine chemotherapy and autologous peptide-loaded dendritic cell (DC) vaccination may improve survival of stage IV melanoma patients. Furthermore, a small cohort of long-term survivors was studied in more detail. PATIENTS AND METHODS: Between 1998 and 2008, 41 patients were vaccinated at least three times with DCs while receiving chemotherapy and compared to all other 168 patients in our database who only received chemotherapy (1993-2008). RESULTS: Median life expectancy of patients receiving additional DC-vaccination was 18 months, compared to eleven months for patients under standard chemotherapy alone. In contrast to patients with other haplotypes, the HLA-A1/A1 subset of DC-treated patients showed significantly lower median survival (12 vs. 25 months). Autoantibodies were frequently detected in serum of both vaccinated and non-vaccinated patients, and there was no correlation between titers, loss or appearance of autoantibodies and survival. Additionally, phenotyping of DCs and PBMCs also did not reveal any conspicuous correlation with survival. CONCLUSIONS: Combining standard chemotherapy and DC vaccination appears superior to chemotherapy alone. The impact of HLA haplotypes on survival emphasizes the importance of a careful selection of patients with specific, well-defined HLA haplotypes for future vaccination trials using peptide-pulsed DCs, possibly combined with checkpoint inhibitors.
Authors: Peter Hersey; Scott W Menzies; Gary M Halliday; Tam Nguyen; Margaret L Farrelly; Chitra DeSilva; Margaret Lett Journal: Cancer Immunol Immunother Date: 2003-11-05 Impact factor: 6.968
Authors: Stefanie Gross; Michael Erdmann; Ina Haendle; Steve Voland; Thomas Berger; Erwin Schultz; Erwin Strasser; Peter Dankerl; Rolf Janka; Stefan Schliep; Lucie Heinzerling; Karl Sotlar; Pierre Coulie; Gerold Schuler; Beatrice Schuler-Thurner Journal: JCI Insight Date: 2017-04-20
Authors: Stefanie K Wculek; Francisco J Cueto; Adriana M Mujal; Ignacio Melero; Matthew F Krummel; David Sancho Journal: Nat Rev Immunol Date: 2019-08-29 Impact factor: 53.106
Authors: I Truxova; M Hensler; P Skapa; M J Halaska; J Laco; A Ryska; R Spisek; J Fucikova Journal: Int Rev Cell Mol Biol Date: 2016-11-29 Impact factor: 6.813
Authors: M E Christine Lutsiak; Roshanak T Semnani; Roberto De Pascalis; Syed V S Kashmiri; Jeffrey Schlom; Helen Sabzevari Journal: Blood Date: 2004-12-09 Impact factor: 22.113
Authors: Julia A Brown; David M Dorfman; Feng-Rong Ma; Elizabeth L Sullivan; Oliver Munoz; Clive R Wood; Edward A Greenfield; Gordon J Freeman Journal: J Immunol Date: 2003-02-01 Impact factor: 5.422
Authors: B Thurner; I Haendle; C Röder; D Dieckmann; P Keikavoussi; H Jonuleit; A Bender; C Maczek; D Schreiner; P von den Driesch; E B Bröcker; R M Steinman; A Enk; E Kämpgen; G Schuler Journal: J Exp Med Date: 1999-12-06 Impact factor: 14.307
Authors: Eike-Christian Wamhoff; Jessica Schulze; Lydia Bellmann; Mareike Rentzsch; Gunnar Bachem; Felix F Fuchsberger; Juliane Rademacher; Martin Hermann; Barbara Del Frari; Rob van Dalen; David Hartmann; Nina M van Sorge; Oliver Seitz; Patrizia Stoitzner; Christoph Rademacher Journal: ACS Cent Sci Date: 2019-05-10 Impact factor: 14.553
Authors: Steve Boudewijns; Martine Bloemendal; Nienke de Haas; Harm Westdorp; Kalijn F Bol; Gerty Schreibelt; Erik H J G Aarntzen; W Joost Lesterhuis; Mark A J Gorris; Alexandra Croockewit; Lieke L van der Woude; Michelle M van Rossum; Marieke Welzen; Anna de Goede; Stanleyson V Hato; Winette T A van der Graaf; Cornelis J A Punt; Rutger H T Koornstra; Winald R Gerritsen; Carl G Figdor; I Jolanda M de Vries Journal: Cancer Immunol Immunother Date: 2020-01-24 Impact factor: 6.968
Authors: Iris A E van der Hoorn; Georgina Flórez-Grau; Michel M van den Heuvel; I Jolanda M de Vries; Berber Piet Journal: Front Immunol Date: 2021-06-28 Impact factor: 7.561